Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)

被引：0

作者：

Navarro Martin, M. ^{[1
]}

Teran Brage, E. ^{[1
]}

Campana-Diaz, E. ^{[2
]}

Garcia-Talavera, P. ^{[2
]}

Reguera Puertas, P. ^{[1
]}

Rama-Alonso, S. ^{[2
]}

Garijo-Martinez, M. C. ^{[1
]}

Felix, L. C. ^{[1
]}

Diaz Sanchez, P. ^{[1
]}

Vidal Tocino, R. ^{[1
]}

Fonseca Sanchez, E. ^{[1
]}

机构：

[1] Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain

[2] Univ Hosp Salamanca, Dept Nucl Med, Salamanca, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.227

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

219P

引用

页码：S95 / S95

页数：1

共 50 条

[1] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
Mok, S.
Tay, Y.
Ng, D.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
[2] 177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting
Sassic, Jessica
Farasat, Sadaf
Hermel, David
Sigal, Darren
Xavier, Marin Feldman
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Swiha, Mina M.
Sutherland, Duncan E. K.
Sistani, Golmehr
Khatami, Alireza
Abazid, Rami M.
Mujoomdar, Amol
Wiseman, Daniele P.
Romsa, Jonathan G.
Reid, Robert H.
Laidley, David T.
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
[4] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Mina M. Swiha
Duncan E. K. Sutherland
Golmehr Sistani
Alireza Khatami
Rami M. Abazid
Amol Mujoomdar
Daniele P. Wiseman
Jonathan G. Romsa
Robert H. Reid
David T. Laidley
[J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
[5] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
Bodei, L.
Cremonesi, M.
Grana, C.
Bartolomei, M.
Baio, S.
Bufi, G.
Fiorenza, M.
Obenaus, E.
Paganelli, G.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
[6] 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: A real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center.
Nalder, Mark
Ladwa, Rahul
Raina, Anant
Burge, Matthew E.
Love, Amanda
Pattison, David A.
Ramsay, Stuart
Wyld, David
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
Jahn, U. M. M.
Ilan, E.
Sandstrom, M.
Bamerny, M.
Garske-Roman, U.
Lubberink, M.
Sundin, A.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
[8] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
Jahn, Ulrika
Ilan, Ezgi
Sandstrom, Mattias
Garske-Roman, Ulrike
Lubberink, Mark
Sundin, Anders
[J]. NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
[9] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
Marin, G.
Vanderlinden, B.
Wimana, Z.
Guiot, T.
Karfis, I.
Flamen, P.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
[10] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
Abou Jokh Casas, E.
Pombo Pasin, M. D.
Pubul Nunez, V.
Garrido Pumar, M.
Blanco Freire, M. N.
Cabezas, J.
Cameselle, J.
Berrios, M.
Argibay, S.
Ruibal Morell, A.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598

← 1 2 3 4 5 →